Medical

Home>Medical
Apr 4 2022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

By |2022-04-05T20:32:09-04:00April 4th, 2022|Investor News, Medical, News, Press Releases|Comments Off on Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro.  Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...

Mar 1 2022

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant

By |2022-03-01T10:07:25-05:00March 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen.  The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies.  The results are shown ...

Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Feb 1 2022

Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture

By |2022-01-31T18:55:40-05:00February 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Tau has been shown to be important in the development of Alzheimer’s Disease. Eradication of tau accomplished without reducing levels of non-target cytokine. Jackson Center, PA, February 1, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to selectively reduce and control the level of one element in a heterogeneous mixture containing two elements ...

Dec 20 2021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

By |2021-12-19T18:05:14-05:00December 20th, 2021|Investor News, Medical, News|0 Comments

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below).  Interleukin-2 ...

Dec 15 2021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

By |2021-12-14T20:33:30-05:00December 15th, 2021|Investor News, Medical, News|0 Comments

Jackson Center, PA, December 15, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer’s Disease or mild cognitive impairment.  Halberd’s demonstrated ability to control the ...

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By |2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Oct 25 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

By |2021-10-24T19:32:33-04:00October 25th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity.  Removal of these obesity-related target elements would reduce or eliminate ...

Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By |2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Go to Top